Acrivon Therapeutics reported a net loss of $21.0 million for the second quarter ended June 30, 2025, an increase from the $18.8 million net loss for the same period in 2024. Research and development expenses for the quarter were $16.2 million, up from $15.0 million in Q2 2024, primarily due to increased personnel supporting the clinical trials for ACR-368 and ACR-2316.
The company highlighted continued positive clinical data for ACR-368, noting deep and durable responses in patients with aggressive endometrial cancer who had progressed on prior chemotherapy and anti-PD1 therapy. Acrivon also indicated an opportunity to expand the patient population benefiting from ACR-368 by exploring its combination with ultra low-dose gemcitabine in biomarker-unselected second-line patients.
For ACR-2316, initial clinical activity was observed during dose escalation in several solid tumor types, including an ongoing confirmed partial response in endometrial cancer. As of June 30, 2025, Acrivon's cash, cash equivalents, and investments totaled $147.6 million, providing a projected cash runway into the second quarter of 2027.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.